Sign In
Buy NBIX
$165.11
+10.27 (+6.63%)
At Close: Jun 03, 2026
/C O R R E C T I O N -- Neurocrine Biosciences, Inc./
03:01pm, Monday, 08'th Jun 2020
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced positive data from its completed open-label, multiple-dose, dose-finding, Phase II clinical study of crinecerfont (NBI-74788), demonstrating
Offshore regulator clears Santos’ plan for drilling location survey - DirectorsTalk
09:28am, Monday, 08'th Jun 2020
National Offshore Petroleum Safety and Environmental Management Authority (NOPSEMA) has approved Santos’ plan for a geophysical survey in preparation for the proposed Yoorn-1 well drilling offshore
Wall Street Breakfast: The Week Ahead
12:43pm, Sunday, 07'th Jun 2020
Welcome to Wall Street Brunch, our preview of stock market events for investors to watch during the upcoming week. You can also catch this article a day early b
The Week Ahead In Biotech: Viela FDA Decision, Hematology Conference Take Center Stage
12:00am, Sunday, 07'th Jun 2020
The biotech space saw a flurry of activity last week, with coronavirus-related news, conference presentations and IPOs.
Negative clinical readouts led to some strong selling in...
Stocks To Watch: Buzz On Vroom, Lululemon, GameStop And Sports Betting Plays
12:36pm, Saturday, 06'th Jun 2020
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive th
Biotech Stock To Watch: Why This Leader Could Be Poised For Another Run
03:26pm, Friday, 05'th Jun 2020
Biotech company Neurocrine Biosciences is expected to deliver an update on a rare-disease program next week — offering a potential catalyst for NBIX stock, an analyst said Thursday.
Biotech Stock To Watch: Why This Leader Could Be Poised For Another Run
09:11pm, Thursday, 04'th Jun 2020
Biotech company Neurocrine Biosciences is expected to deliver an update on a rare-disease program next week — offering a potential catalyst for NBIX stock, an analyst said Thursday.
Neurocrine Biosciences to Present at the Goldman Sachs 41st Annual Global Healthcare Conference Webcast
08:01pm, Thursday, 04'th Jun 2020
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Goldman Sachs 41st Annual Global Healthcare Conference Webcast at 9:40 a.m. ET on Thursday, June 11, 2020. Kevin Gorman, Chief Executive
Santos awards KBR GLNG efficiency study contract - DirectorsTalk
02:07pm, Thursday, 04'th Jun 2020
Santos has contracted KBR to undertake an energy efficiency opportunities study at its Gladstone liquified natural gas (GLNG) project in Queensland. The study will explore opportunities to improve the
Investors will have to navigate these three post-pandemic market stages: Goldman Sachs
11:19am, Thursday, 04'th Jun 2020
Daily roundup of research and analysis from The Globe and Mail’s market strategist Scott Barlow
Edited Transcript of NBIX earnings conference call or presentation 6-May-20 8:30pm GMT
05:44am, Wednesday, 03'rd Jun 2020
Q1 2020 Neurocrine Biosciences Inc Earnings Call
APPEA emphasises industry role in Australian economy - DirectorsTalk
08:47am, Tuesday, 02'nd Jun 2020
Australian Petroleum Production and Exploration Association (APPEA) has highlighted the critical role oil and gas plays in providing energy to the Australian industry and households. The association�
Beware Anchoring Bias: Top Stocks Now
06:52am, Tuesday, 02'nd Jun 2020
Focus more on businesses and less on anchoring to past prices. Uncertainty is increasing with the S&P 500 in no man's land. The best sectors across large cap, m
AbbVie Gets FDA Nod for Oriahnn to Control Menstrual Bleeding
03:46pm, Monday, 01'st Jun 2020
The FDA approves AbbVie's (ABBV) Oriahnn oral capsule for checking heavy menstrual bleeding related to uterine fibroids in pre-menopausal women. It will be sold in US markets by June-end.
